Evidence map›Paper›PMID 39896882›Full record

ArticleAdvanced functional materials2024

N-Dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL-1β Productions for Antitumor Immunity.

Ashley R Hoover, Kaili Liu, Coline Furrer, Samuel Siu Kit Lam, David W Anderson, Zhijun Zhou, Jingxuan Yang, Chun Fung Wong, Alexandra D Medcalf, Xiao-Hong Sun and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ashley R HooverStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Kaili LiuStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Coline FurrerStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Samuel Siu Kit LamImmunophotonics, Inc., Saint Louis, MO, USA.
David W AndersonImmunophotonics, Inc., Saint Louis, MO, USA.
Zhijun ZhouDepartment of Medicine, Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Jingxuan YangDepartment of Medicine, Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Chun Fung WongImmunophotonics, Inc., Saint Louis, MO, USA.
Alexandra D MedcalfArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Xiao-Hong SunArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Tomas HodeImmunophotonics, Inc., Saint Louis, MO, USA.
Lu AlleruzzoImmunophotonics, Inc., Saint Louis, MO, USA.
Abby DelawderImmunophotonics, Inc., Saint Louis, MO, USA.
Joseph RakerImmunophotonics, Inc., Saint Louis, MO, USA.
Ghainaa AbousleimanStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Trisha I ValerioStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Yuanhong SunStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
James F PapinDepartment Pathology and Division of Comparative Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Min LiDepartment of Medicine, Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Wei R ChenStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.

Funding

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumorsR01CA269897 · NCI · UNIVERSITY OF OKLAHOMA · PI Wei R. Chen, MIN LI · 2022 to 2026
$2.5M
Mechanistic study on synergistic photo-immunological effects of laser immunotherapy for metastatic cancersR01CA205348 · NCI · UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · 2017 to 2021
$1.5M
NCI NIH HHS R01 CA205348NCI NIH HHS R01 CA269897
6 · The paper itself

Abstract

N-dihydrogalactochitosan (GC) is an immune stimulant/adjuvant. Synthesized from chitosan and galactose, GC is a new chemical entity that significantly enhances the immune-stimulating properties of its parental material, chitosan, making it a promising therapeutic agent. When used in combination with antigenic material, GC stimulates innate and adaptive antitumor and antiviral immunities. However, its mechanism has not been fully investigated. Herein we demonstrate that GC drives type I IFN activation in antigen-presenting cells (APCs). More importantly, GC drives alternative STING pathways, leading to inflammatory cell death that enhances dendritic cell (DC) activation. GC-activated DCs trigger a variety of nucleic acid sensing pattern recognition receptors (PRRs) pathways and IL-1β production via the activation of the inflammasome.

Indexed as

antitumor and antiviral immunitiesChitosaninterleukin 1β (IL-1β)N-dihydrogalactochitosan (GC, IP-001)pattern recognition receptors (PRRs)stimulator of interferon genes (STING)type I interferons (IFNs)

Identifiers

PMID39896882
PMCPMC11784597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.